Skip to content

Comparison Of Urinary Beta-2 Microglobulin Levels in Children and Adolescents with Nephrotic Syndrome

Estimation Of Urinary Beta-2 Microglobulin Levels In Children And Adolescents With Nephrotic Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/04/018391
Enrollment
60
Registered
2019-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes

Interventions

Control Intervention1: Nil: Nil

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children and adolescents with steroid sensitive and steroid resistant nephrotic syndrome (with atleast 1year of treatment with calcineurin inhibitor) who are currently in complete or partial remission

Exclusion criteria

Exclusion criteria: Children with congenial nephrotic syndrome, having an active urinary tract infection. Presently having acute kidney injury or chronic kidney injury will be excluded from the study

Design outcomes

Primary

MeasureTime frame
Measurement of spot urinary Beta-2 Microglobulin Levels In Patients With Steroid Sensitive And Steroid Resistant Nephrotic SyndromeTimepoint: Estimation of urinary Beta-2 Microglobulin will be done once in time period of 1year

Secondary

MeasureTime frame
Comparison of urinary Beta-2 Microglobulin Levels between patients with steroid sensitive and steroid resistant nephrotic syndrome. Correlation of Urinary Beta-2 Microglobulin Levels to 24 hr Urinary Sodium, Creatinine and Protein LevelsTimepoint: This assessment will be done once in period of 1year

Countries

India

Contacts

Public ContactDrDeepika

Maulana Azad Medical College

muktamantan@hotmail.com9968604315

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026